[A18-87] Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V

Last updated 20.06.2019

Project no.:

Commission awarded on 19.12.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Head and nerves


Children and adolescents with highly active or rapidly evolving relapsing-remitting multiple sclerosis (RRMS)

Result of dossier assessment:

If RRMS is highly active and switch of basic therapeutic agents is indicated despite a full and adequate course of treatment with at least one disease-modifying therapy: hint of non-quantifiable added benefit. Other patient groups: added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2019-06-20 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form